Escolar Documentos
Profissional Documentos
Cultura Documentos
ABSTRACT
Functional dyspepsia (FD) is a disorder presenting with symptoms such as postprandial fullness,
early satiety or epigastric pain. Although there is a 10 to 30% reported prevalence worldwide, there is
currently no clear explanation of the pathophysiology behind this condition. Motility disorders, visceral
hypersensitivity, acid disorders, Helicobacter pylori infection or psychosocial factors have all been re-
ported to play a part in the pathophysiology of FD. The diagnosis of FD is one of exclusion, based on
the Rome III criteria. The main therapeutic modalities include lifestyle changes, eradicating Helicobacter
pylori infection and treatment with either proton pump inhibitors, prokinetics or antidepressants.
Article received on the 22nd of November 2012. Article accepted on the 15th of January 2013.
the fact that the positive predictive value of copy (40-42) has the advantage of excluding
these symptoms is low (11%). However, their peptic ulcer, esophagitis and cancer as causes
negative predictive value in excluding gastroin- of dyspepsia. A meta-analysis of nine studies
testinal malignancy is very high, approximately with 5389 patients showed that the most com-
97% (36). This is the logical consequence of the mon finding in patients with dyspeptic symp-
fact that only 2% of dyspeptic syndromes are toms was erosive esophagitis (pooled preva-
caused by esophageal or gastric cancer, 30 lence 13%), though the prevalence was much
times fewer than functional dyspepsia (37). lower when dyspepsia was defined using the
Conversely, the presence of alarm symptoms Rome criteria (6 %) (43).
provides reasonable guidance, and has been In addition, clinical trials show that simply
included in consensus recommendations on being subjected to an endoscopic study in-
functional dyspepsia management. creases the patient’s level of satisfaction and
Excluding gastroesophageal reflux disease confidence (44). Supporters of empiric therapy
(GERD) as the cause of dyspeptic symptoms is argue that a low incidence of cancer (less
also of paramount importance because GERD than 2% of dyspeptic patients) and the high
has a different treatment and prognosis and re- costs in-curred by endoscopy should preclude
quires a particular management strategy involv- upper digestive endoscopy as a first step in
ing long-term proton pump inhibitor therapy investigat-ing these patients. Accordingly,
(IPP) and active surveillance for reflux esopha- patients under 45-50 years of age without any
gitis, Barrett’s esophagus as well as esophageal alarm symp-toms could be treated empirically
cancer. Many GERD patients are diagnosed with with minimal risks (45), endoscopic studies
functional dyspepsia because of the lack of being reserved for those patients who are
structural abnormalities in endoscopic stud-ies nonresponsive to 6-8 weeks of therapy.
and the great variety of symptoms of func-tional However, given that many patients do not
dyspepsia (including heartburn) which in turn achieve full symptomatic relief with medical
has lead to confusing results in many clini-cal therapy, requiring further investigations, it
trials (38). seems more prudent to per-form endoscopy in
A drug-induced dyspepsia must be also tak- the initial workup. If this initial endoscopic
en into account, especially nonsteroidal anti- study is normal, endoscopy will not be
inflammatory drugs (NSAIDs) commonly asso- repeated unless alarm symptoms develop.
ciated with dyspepsia. In this case, the offending The American Gastroenterology Associa-
agent should be discontinued, if possible, or a tion’s guidelines from 2005 also suggest that
proton pump inhibitor can be added (PPI) (39). endoscopy should be performed in patients with
Patients on long term NSAID treatment can be dyspepsia who have alarm symptoms or those
considered at risk for peptic ulcer disease and without alarm symptoms who are ≥55 years of
the physician should decide whether endosco-py age (46). The authors point out that in some
is warranted from the first visit. regions where cancer incidence is higher (such
The optimal approach for a patient with as Alaska), lower age thresholds are ap-
un-investigated dyspeptic symptoms is far propriate, for example 45 years rather than 55
from be-ing decided. Several strategies for years of age. Patients who receive medication
the manage-ment of these patients have should be evaluated for symptomatic improve-
been proposed, but several systematic ment at approximately eight weeks.
reviews have failed to settle the dispute.
The options taken into discussion were: 2. Empiric antisecretory therapy
1. Prompt endoscopy The empiric antisecretory therapy has ad-
2. Empiric antisecretory therapy vantages and disadvantages, according to con-
3. Noninvasive testing for Helicobacter flicting results of studies. Many patients can
pylori, followed by treatment or endoscopy if have a favorable symptomatic response, but this
positive (test-and-treat strategy) does not exclude a malignant gastric ulcer and it
can delay the diagnosis. Also, the recur-rence of
1. The role of endoscopy in FD the symptoms is common after one year (47)
The most debated problem in the manage- and the lack of H. pylori eradication increases
ment of FD, as already shown above, is the role the risk of ulcer recurrence.
of an initial upper digestive endoscopy. Endos-
REFERENCES
1. Bazaldua OV, Schneider FD – Evalua- the Migrating Motor Complex. Scand 11. Mearin F, de Ribot X, Balboa A, et al.
tion and Management of Dyspepsia. Am. J Gastroenterol 1996; 31 (11): 1063-8 – Does Helicobacter Pylori Infection
Fam Physician 1999; 60: 1774 7. Feinle C, Read NW – Ondansetron Increases Gastric Sensitivity in
2. Mahadeva S, Gok KL – Epidemiology of Reduces Nausea Induced by Gastro- Functional Dyspepsia? Gut 1995;
Functional Dyspepsia: a Global duodenal Stimulation without Changing 37:47-51
Perspective 2006; 12(17):2661-6 Gastric Motility. Am J Physiol 1996; 12. Lee KJ, Demarchi B, Vos R, et al.
3. Maes BD, Ghoos YF, Hiele MI, et al. 271: G591-7 – Comparison of Duodenal Acid
– Gastric Emptying Rate of Solids in 8. Troncon LE, Thompson DG, Ahluwa-lia Exposure in Functional Dyspepsia
Patients with Nonulcer Dyspepsia. Dig. NK, et al. – Relations between Upper Patients and Healthy Controls Using
Dis Sci 1997; 42:235-42 Abdominal Symptoms and Distension 24-Hour Ambulatory Duodenal Ph
4. Thumshirn M, Camilleri M, Saslow Abnormalities in Dysmotil-ity Like Monitoring. Gastroenterology 2002;
SB, et al. – Gastric Accomodation in Functional Dyspepsia and after 122: A-102
Non-Ulcer Dyspepsia and the Roles of Vagotomy. Gut 1995; 36: 17-22 13. Bratten J, Jones MP – Prolonged
Helicobacter Pylori Infection and Vagal 9. Camilleri M – Functional Dyspepsia; Recording of Duodenal Acid Exposure
Function. Gut 1999; 44:55-64 Mechanisms of Symptom Generation Inpatients with Functional Dyspepsia
5. Takashi T – Mechanisms of Interdiges- and Appropriate Management of and Controls Using a Radiotelemetry
tive Migrating Motor Complex. J Patients. Gastroenterol Clin N Am Ph Monitoring System. J Clin
Neurogastroenterol Motil 2012; 18(3): 2007; 36:643-664 Gastroen-terol 2009; 43(6):527-533
246-257 10. Barbera R, Feinle C, Read NW 14. Moayyedi P, Soo S, Deeks J, et al.
6. Testoni PA, Bagnolo F, Bologna P, et – Nutrient-specific modulation of – Eradication of Helicobacter Pylori for
al. – Higher Prevalence of Helicobacter gastric mechanosensitivity in patients Non-Ulcer Dyspepsia. Cochrane
Pylori Infection in Dyspeptic Patients with functional dyspepsia. Dig Dis Sci Database Syst Rev 2006; (2):CD002096
who Do Not Have Gastric Phase IIII of 1995; 40:1636-41 15. Loyd RA, McClellan DA – Update on
the Evaluation and Management of Clin Gastroenterol 2009; 43(8):716-722 37. Bazaldua OV, Schneider FD – Evalua-
Functional Dyspepsia. Am Fam 25. Tack J, Tallez NJ, Camilleri M, et al. tion and Management of Dyspepsia. Am.
Physician 2011; 83(5):547-52 – Functional Gastroduodenal Disorders. Fam Physician 1999; 60:1774
16. Danesh J, Lawrence M, Murphy M, et Gastroenterology 2006; 130:1466-79 38. Talley NJ, Meineche-Scmidt V, Pare P,
al. – Systematic Review of the Epide- 26. Drossman DA – Rome III: the New et al. – Efficacy of Omeprazol in
miological Evidence on Helicobacter Criteria. Chin J Dig Dis. 2006; 7(4):181-5 Functional Dyspepsia: Double-Blind,
Pylori Infection and Nonulcer or 27. Simren M, Tack J – Functional Randomized, Placebo-Controlled Trial
Uninvestigated Dyspepsia. Arch Intern Dyspepsia: Evaluation and Treatment. (The Bond and Opera Studies). Aliment
Med 2000; 160:167-80 Gastroenterol Clin N Am. 2003; Pharmacol Ther 1998; 12:1055-1065
17. Budavari AI, Olden KW – Psychosocial 32:577-599 39. Talley NJ – American Gastroentero-
Aspects of Functional Gastrointestinal 28. van Marrewijk CJ, Mujakovic S, logical Association Medical Position
Disorders. Gastroenterol Clin North Am Fransen GA, et al. – Effect and Cost- Statement: Evaluation of Dyspepsia.
2003; 32:477-506 Effectiveness of Step-Up versus Step- Gastroenterology 2005; 129:1753-5
18. Lee HJ, Lee SY, Kim JH, et al. Down Treatment with Antacids, H2- 40. ASGE – The Role of Endoscopy in
– Depressive Mood and Quality of Life Receptor Antagonists and Proton Dyspepsia. Gastrointest Endosc.
in Functional Gastrointestinal Disor- Pump Inhibitors in Patients with New 2007; 66(6):1071-5
ders: Differences Between Functional Onset Dyspepsia (DIAMOND study): a 41. Lassen AT, Pedersen FM, Bytzer P, et
Dyspepsia, Irritable Bowel Syndrome Primary-Care-Based Randomised al. – Helicobacter Pylori Test and
and Overlap Syndrome. Gen Hosp Controlled Trial. Lancet 2009; Eradicate versus Prompt Endoscopy for
Psychiatry 2010; 32(5):499-502 373(9659): 215 Management of Dyspeptic Patients – a
19. van Kerkhoven LA, Laheij RJ, Aparicio 29. Peura DA, Kovacs TO, Metz DC, et al. Randomized Trial. Lancet 2000;
N, et al. – Effect of the Antidepressant – Lansoprazole in the Treatment of 356:455-60
Venlafaxine in Functional Dyspepsia: a Functional Dyspepsia: Two Double- 42. Talley N, Silverstein M, et al. – AGA
Randomized, Double-Blind, Placebo- Blind, Randomized, Placebo-Controlled Technical Review: Evaluation of
Controlled Trial. Clin Gastroenterol Trials. Am J Med 2004; 116(11): 740 Dyspepsia. Gastroenterology 1998; 114
Hepatol 2008; 6(7):746 30. Abraham NS, Moayyedi P, Daniels B, et (3):582-595
20. Zuo XL, Li YQ, Li WJ, et al. – Altera- al. – Systematic Review: the 43. Ford AC, Marwaha A, Lim A, et al.
tions of Food Antigen-Specific Serum Methodological Quality of Trials Affects – What Is the Prevalence of Clinically
Immunoglobulins G and E Antibodies Estimates of Treatment Efficacy in Significant Endoscopic Findings in
in Patients with Irritable Bowel Functional (Non-Ulcer) Dyspepsia. Subjects with Dyspepsia? Systematic
Syndrome and Functional Dyspepsia. Aliment Pharmacol Ther 2004; 19(6):631 Review and Meta-Analysis. Clin
Clin Exp Allergy 2007; 37:823-30 31. Tack J, Tallez NJ, Camilleri M, et al. Gastroenterol Hepatol 2010; 8(10):830
21. Friesen CA, Sandridge L, Andre L, – Functional Gastroduodenal Disorders. 44. Rabeneck L, Wristers K, Souchek J, et
et al. – Mucosal Eosinophilia and Gastroenterology 2006; 130:1466-79 al. – Impact of Upper Endoscopy on
Response to H1/H2 Antagonist and 32. Soo S, Moayyedi P, Deeks J, et al. Satisfaction in Patients with Previously
Cromolyn Therapy in Pediatric – Pharmacological Interventions for Uninvestigated Dyspepsia. Gastrointes-
Dyspepsia. Clin Pediatr (Phila) 2006; Non-Ulcer Dyspepsia. Cochrane tinal Endoscopy 2003; 57(3):295-9
45:143-7 Database Syst Rev 2000 45. Health and Public Policy Committee
22. Talley NJ, Vakil N, Lauritsen K, et al. 33. Talley NJ, Tack J, Ptak T, et al. – Endoscopy in the Evaluation of
and STARS I Study Group – Random- – Itopride in Functional Dyspepsia: Dyspepsia. Ann Intern Med. 1985;
ized Controlled Trial of Esomeprazole-in Results of Two Phase III Multicentre, 102: 266-269
Functional Dyspepsia Patients with Randomised, Double-Blind, Placebo- 46. Talley NJ, American
Epigastric Pain or Burning: Does a One Controlled Trials. Gut 2008; 57(6):740 Gastroenterologi-cal Association,
Week Trial of Acid Suppression Predict 34. van Kerkhoven LA, Laheij RJ, Aparicio American Gastroen-terological
Symptom Response? Aliment Pharmacol N, et al. – Effect of the Antidepressant Association – Medical Position
Ther 2009; 26(5):673-682 Venlafaxine in Functional Dyspepsia: a Statement: Evaluation Of Dyspepsia.
23. Thomson AB, Barkun AN, Armstron Randomized, Double-Blind, Placebo- Gastroenterology 2005; 129(5):1753
D et al. – The Prevalence of Clinically Controlled Trial. Clin Gastroenterol 47. Rabeneck L, Souchek J, Wristers K,
Significant Endoscopic Findings in Hepatol 2008; 6(7):746 et al. – A Double Blind, Randomized,
Primary Care Patients with Uninvesti- 35. Miwa H, Ghoshal UC, Gonlachanvit Placebo-Controlled Trial of Proton
gated Dyspepsia: the Canadian Adult SJ – Asian Consensus Report on Pump Inhibitor Therapy in Patients
Dyspepsia Empiric Treatment – Prompt Functional Dyspepsia. Neurogastroen- with Uninvestigated Dyspepsia. Am J
Endoscopy (CADET PE) study. Aliment terol Motil 2012; 18(2):150-68. Epub, Gastroenterol 2002; 97:3045
Pharmacol Ther 2003; 17:1481-1491 2012 April 9th. 48. Malfertheiner P, Megraud F, O’Morain
24. Sha W, Pasricha PJ, Chen JD – Correla- 36. Mahadeva S, Gok KL – Epidemiology of C, et al. – Current Concepts in the
tions among Electrogastrogram, Gastric Functional Dyspepsia: a Global Management of Helicobacter Pylori
Dysmotility and Duodenal Dysmotility in Perspective. World J Gastroenterol Infection: the Maastricht III Consensus
Patients with Functional Dyspepsia. J 2006; 12(17):2661-6 Report. Gut 2007; 56(6):772.